PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 14619337-9 2003 Inhibition of CysLTs by 10 microM of montelukast was noted in 5 patients with RW and in 10 patients with M. Levels of RANTES in some patients were increased by both allergens without consistent inhibitory effects of montelukast. montelukast 37-48 C-C motif chemokine ligand 5 Homo sapiens 118-124 24080250-9 2013 Montelukast significantly suppressed the release of IL-8 (p = 0.016), IL-6 (p = 0.006), RANTES (p = 0.002) and IFN-gamma (p = 0.046), in a dose dependent manner in unstimulated cultures but not in those stimulated with IL-1/TNF. montelukast 0-11 C-C motif chemokine ligand 5 Homo sapiens 88-94 24080250-10 2013 Withdrawal of Montelukast treatment, was associated with increased IL-8 and RANTES secretion in unstimulated nasal AEC cultured from subjects with asthma and allergic rhinitis but not with asthma alone. montelukast 14-25 C-C motif chemokine ligand 5 Homo sapiens 76-82 24080250-11 2013 CONCLUSIONS: Montelukast treatment for asthma symptoms reversibly suppresses nasal AEC release of pro-inflammatory mediators (i.e. IL-8 and RANTES) but only in those cells cultured from subjects with concomitant allergic rhinitis. montelukast 13-24 C-C motif chemokine ligand 5 Homo sapiens 140-146